{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T20:03:37Z","timestamp":1788897817062,"version":"build-2803163510"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T00:00:00Z","timestamp":1640304000000},"content-version":"am","delay-in-days":326,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.jconrel.2020.11.031","type":"journal-article","created":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T20:50:09Z","timestamp":1605819009000},"page":"284-292","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["A macrophage-targeted platform for extending drug dosing with polymer prodrugs for pulmonary infection prophylaxis"],"prefix":"10.1016","volume":"330","author":[{"given":"Thomas E.J.","family":"Chavas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang-Yi","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selvi","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debashish","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Lovelace-Macon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilhem F.","family":"Rerolle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Limqueco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn J.","family":"Skerrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M.","family":"Ratner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. Eoin","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick S.","family":"Stayton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.jconrel.2020.11.031_bb0005","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1586\/14787210.2013.840534","article-title":"Antimicrobial therapies for Q fever","volume":"11","author":"Kersh","year":"2013","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"10.1016\/j.jconrel.2020.11.031_bb0010","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2147\/IDR.S105473","article-title":"Drug resistance in influenza A virus: the epidemiology and management","volume":"10","author":"Hussain","year":"2017","journal-title":"Infect. Drug Resist."},{"key":"10.1016\/j.jconrel.2020.11.031_bb0015","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.coph.2018.05.013","article-title":"Drug-resistant tuberculosis: challenges and opportunities for diagnosis and treatment","volume":"42","author":"Koch","year":"2018","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.jconrel.2020.11.031_bb0020","series-title":"Legionellosis, Infections of the Central Nervous System","first-page":"383","author":"Johnson","year":"2020"},{"issue":"5","key":"10.1016\/j.jconrel.2020.11.031_bb0025","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s10096-019-03771-0","article-title":"Pulmonary non-tuberculous mycobacterial infections: current state and future management","volume":"39","author":"Chin","year":"2020","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.jconrel.2020.11.031_bb0030","author":"CDC"},{"issue":"44","key":"10.1016\/j.jconrel.2020.11.031_bb0035","doi-asserted-by":"crossref","first-page":"5981","DOI":"10.1016\/j.vaccine.2017.03.022","article-title":"Burkholderia pseudomallei and Burkholderia mallei vaccines: are we close to clinical trials?","volume":"35","author":"Titball","year":"2017","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.jconrel.2020.11.031_bb0040","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.immuni.2020.03.007","article-title":"SARS-CoV-2 vaccines: status report","volume":"52","author":"Amanat","year":"2020","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.jconrel.2020.11.031_bb0045","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1128\/CMR.00101-15","article-title":"Inhaled antibiotics for gram-negative respiratory infections","volume":"29","author":"Wenzler","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"issue":"2","key":"10.1016\/j.jconrel.2020.11.031_bb0050","doi-asserted-by":"crossref","first-page":"156","DOI":"10.4065\/mcp.2010.0639","article-title":"General principles of antimicrobial therapy","volume":"86","author":"Leekha","year":"2011","journal-title":"Mayo Clin. Proc."},{"issue":"6","key":"10.1016\/j.jconrel.2020.11.031_bb0055","first-page":"ME05","article-title":"Burden of antibiotic resistance in common infectious diseases: role of antibiotic combination therapy","volume":"8","author":"Mehta","year":"2014","journal-title":"J. Clin. Diagn. Res."},{"issue":"3","key":"10.1016\/j.jconrel.2020.11.031_bb0060","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1513\/AnnalsATS.201311-395FR","article-title":"Inhaled antibiotics for lower airway infections","volume":"11","author":"Quon","year":"2014","journal-title":"Ann. Am. Thoracic Soc."},{"issue":"10","key":"10.1016\/j.jconrel.2020.11.031_bb0065","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.drudis.2018.05.017","article-title":"Current approaches to the discovery of novel inhaled medicines","volume":"23","author":"Strong","year":"2018","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2020.11.031_bb0070","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3389\/fmicb.2017.00091","article-title":"Inhaled liposomal ciprofloxacin protects against a lethal infection in a murine model of pneumonic plague","volume":"8","author":"Hamblin","year":"2017","journal-title":"Front. Microbiol."},{"issue":"9","key":"10.1016\/j.jconrel.2020.11.031_bb0075","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.1128\/AAC.03443-14","article-title":"Efficacy of liposome-encapsulated ciprofloxacin in a murine model of Q fever","volume":"58","author":"Norville","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.jconrel.2020.11.031_bb0080","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1128\/AAC.02555-13","article-title":"Liposome encapsulation of ciprofloxacin improves protection against highly virulent Francisella tularensis strain Schu S4","volume":"58","author":"Hamblin","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2020.11.031_bb0085","doi-asserted-by":"crossref","first-page":"915","DOI":"10.3389\/fmicb.2018.00915","article-title":"Amikacin liposome inhalation suspension (ALIS) penetrates non-tuberculous mycobacterial biofilms and enhances Amikacin uptake into macrophages","volume":"9","author":"Zhang","year":"2018","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.jconrel.2020.11.031_bb0090","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1146\/annurev-pharmtox-010611-134623","article-title":"Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective","volume":"52","author":"Moghimi","year":"2012","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"1","key":"10.1016\/j.jconrel.2020.11.031_bb0095","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.addr.2012.11.006","article-title":"Pharmacokinetic considerations for targeted drug delivery","volume":"65","author":"Yamashita","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.jconrel.2020.11.031_bb0100","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/0304-4165(86)90120-0","article-title":"Fate of N-(2-hydroxypropyl)methacrylamide copolymers with pendent galactosamine residues after intravenous administration to rats","volume":"880","author":"Duncan","year":"1986","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"issue":"1","key":"10.1016\/j.jconrel.2020.11.031_bb0105","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/polc.5070510111","article-title":"Structure and properties of pharmacologically active polymers","volume":"51","author":"Ringsdorf","year":"1975","journal-title":"J. Polym. Sci. Polym. Symp."},{"issue":"1","key":"10.1016\/j.jconrel.2020.11.031_bb0110","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0168-3659(87)90085-X","article-title":"Targetable polymeric prodrugs","volume":"6","author":"Kope\u010dek","year":"1987","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.jconrel.2020.11.031_bb0115","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1055\/s-0034-1398389","article-title":"Melioidosis: evolving concepts in epidemiology, pathogenesis, and treatment","volume":"36","author":"Currie","year":"2015","journal-title":"Sem. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.jconrel.2020.11.031_bb0120","doi-asserted-by":"crossref","DOI":"10.1038\/nmicrobiol.2015.8","article-title":"Predicted global distribution of Burkholderia pseudomallei and burden of melioidosis","volume":"1","author":"Limmathurotsakul","year":"2016","journal-title":"Nat. Microbiol."},{"issue":"3","key":"10.1016\/j.jconrel.2020.11.031_bb0125","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/cid\/cir808","article-title":"Clinical features and epidemiology of melioidosis pneumonia: results from a 21-year study and review of the literature","volume":"54","author":"Meumann","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jconrel.2020.11.031_bb0130","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3389\/fmicb.2011.00170","article-title":"Strategies for intracellular survival of Burkholderia pseudomallei","volume":"2","author":"Allwood","year":"2011","journal-title":"Front. Microbiol."},{"issue":"4","key":"10.1016\/j.jconrel.2020.11.031_bb0140","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ijantimicag.2014.01.005","article-title":"Treatment and prophylaxis of melioidosis","volume":"43","author":"Dance","year":"2014","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"4","key":"10.1016\/j.jconrel.2020.11.031_bb0145","first-page":"277","article-title":"The antibiotic resistance crisis: part 1: causes and threats","volume":"40","author":"Ventola","year":"2015","journal-title":"P T"},{"issue":"3","key":"10.1016\/j.jconrel.2020.11.031_bb0150","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1586\/eri.10.4","article-title":"Present and future therapeutic strategies for melioidosis and glanders","volume":"8","author":"Estes","year":"2010","journal-title":"Expert Rev. Anti-Infect. Ther."},{"issue":"8","key":"10.1016\/j.jconrel.2020.11.031_bb0155","doi-asserted-by":"crossref","DOI":"10.1097\/CCM.0000000000001698","article-title":"Increasing experience with melioidosis and critical care: medical and military implications*","volume":"44","author":"MacLaren","year":"2016","journal-title":"Crit. Care Med."},{"issue":"5","key":"10.1016\/j.jconrel.2020.11.031_bb0160","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0035-9203(97)90044-4","article-title":"Oral fluoroquinolones for maintenance treatment of melioidosis","volume":"91","author":"Chaowagul","year":"1997","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"issue":"27","key":"10.1016\/j.jconrel.2020.11.031_bb0165","doi-asserted-by":"crossref","first-page":"4494","DOI":"10.1039\/C6PY00756B","article-title":"Chemotherapeutic copolymers prepared via the RAFT polymerization of prodrug monomers","volume":"7","author":"Son","year":"2016","journal-title":"Polym. Chem."},{"issue":"5","key":"10.1016\/j.jconrel.2020.11.031_bb0170","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1021\/acs.molpharmaceut.6b01178","article-title":"Enzyme-cleavable polymeric micelles for the intracellular delivery of proapoptotic peptides","volume":"14","author":"Kern","year":"2017","journal-title":"Mol. Pharm."},{"issue":"42","key":"10.1016\/j.jconrel.2020.11.031_bb0175","doi-asserted-by":"crossref","first-page":"5224","DOI":"10.1039\/C8PY01047A","article-title":"Fully synthetic macromolecular prodrug chemotherapeutics with EGFR targeting and controlled camptothecin release kinetics","volume":"9","author":"Freeman","year":"2018","journal-title":"Polym. Chem."},{"key":"10.1016\/j.jconrel.2020.11.031_bb0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2018.08.014","article-title":"Macrophage-targeted drugamers with enzyme-cleavable linkers deliver high intracellular drug dosing and sustained drug pharmacokinetics against alveolar pulmonary infections","volume":"287","author":"Su","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.11.031_bb0185","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3389\/fmicb.2010.00141","article-title":"Evaluation of surrogate animal models of melioidosis","volume":"1","author":"Warawa","year":"2010","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.jconrel.2020.11.031_bb0190","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.biomaterials.2018.10.017","article-title":"Glycan targeted polymeric antibiotic prodrugs for alveolar macrophage infections","volume":"195","author":"Chen","year":"2019","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.jconrel.2020.11.031_bb0195","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics8010006","article-title":"Development of liposomal ciprofloxacin to treat lung infections","volume":"8","author":"Cipolla","year":"2016","journal-title":"Pharmaceutics"},{"issue":"5","key":"10.1016\/j.jconrel.2020.11.031_bb0200","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.4269\/ajtmh.2010.10-0306","article-title":"Pathogenicity of high-dose enteral inoculation of Burkholderia pseudomallei to mice","volume":"83","author":"West","year":"2010","journal-title":"Am. J. Trop. Med. Hyg."},{"issue":"11","key":"10.1016\/j.jconrel.2020.11.031_bb0205","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S1473-3099(17)30396-1","article-title":"Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the global burden of disease study 2015","volume":"17","author":"Collaborators","year":"2017","journal-title":"Lancet Infect. Dis."},{"issue":"3","key":"10.1016\/j.jconrel.2020.11.031_bb0210","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00655-2019","article-title":"The global prevalence of latent tuberculosis: a systematic review and meta-analysis","volume":"54","author":"Cohen","year":"2019","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.jconrel.2020.11.031_bb0215","author":"World Health Organization"},{"issue":"11","key":"10.1016\/j.jconrel.2020.11.031_bb0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000900","article-title":"The epidemiology and clinical spectrum of melioidosis: 540 cases from the 20 year Darwin prospective study","volume":"4","author":"Currie","year":"2010","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"5","key":"10.1016\/j.jconrel.2020.11.031_bb0225","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1128\/JCM.43.5.2274-2276.2005","article-title":"Role and significance of quantitative urine cultures in diagnosis of melioidosis","volume":"43","author":"Limmathurotsakul","year":"2005","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.jconrel.2020.11.031_bb0230","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2147\/IDR.S35529","article-title":"Development of ceftazidime resistance in an acute Burkholderia pseudomallei infection","volume":"5","author":"Sarovich","year":"2012","journal-title":"Infect. Drug Resist."},{"issue":"41","key":"10.1016\/j.jconrel.2020.11.031_bb0235","doi-asserted-by":"crossref","first-page":"17165","DOI":"10.1073\/pnas.1111020108","article-title":"Antimicrobial resistance to ceftazidime involving loss of penicillin-binding protein 3 in Burkholderia pseudomallei","volume":"108","author":"Chantratita","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"14","key":"10.1016\/j.jconrel.2020.11.031_bb0240","doi-asserted-by":"crossref","DOI":"10.1128\/genomeA.00053-17","article-title":"Whole-genome sequences of burkholderia pseudomallei isolates exhibiting decreased meropenem susceptibility","volume":"5","author":"Price","year":"2017","journal-title":"Genome Announc."},{"issue":"6","key":"10.1016\/j.jconrel.2020.11.031_bb0245","doi-asserted-by":"crossref","first-page":"e01415","DOI":"10.1128\/genomeA.01427-15","article-title":"Finished annotated genome sequence of burkholderia pseudomallei strain bp1651, a multidrug-resistant clinical isolate","volume":"3","author":"Bugrysheva","year":"2015","journal-title":"Genome Announc."},{"key":"10.1016\/j.jconrel.2020.11.031_bb0250","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.curtheres.2014.11.001","article-title":"Ciprofloxacin-induced antibacterial activity is attenuated by phosphodiesterase inhibitors","volume":"77","author":"Masadeh","year":"2015","journal-title":"Curr. Therap. Res. Clin. Exp."},{"issue":"6","key":"10.1016\/j.jconrel.2020.11.031_bb0255","doi-asserted-by":"crossref","first-page":"427","DOI":"10.5694\/j.1326-5377.1992.tb137276.x","article-title":"Melioidosis: when in doubt leave the quinolone alone!","volume":"157","author":"Ashdown","year":"1992","journal-title":"Med. J. Aust."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2020.11.031_bb0260","doi-asserted-by":"crossref","first-page":"24","DOI":"10.4269\/ajtmh.2001.64.24","article-title":"Maintenance therapy of melioidosis with ciprofloxacin plus azithromycin compared with cotrimoxazole plus doxycycline","volume":"64","author":"Chetchotisakd","year":"2001","journal-title":"Am. J. Trop. Med. Hyg."},{"issue":"7","key":"10.1016\/j.jconrel.2020.11.031_bb0265","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00082-17","article-title":"Demonstrating the protective efficacy of the novel Fluoroquinolone Finafloxacin against an inhalational exposure to Burkholderia pseudomallei","volume":"61","author":"Barnes","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.jconrel.2020.11.031_bb0270","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/jac\/dki039","article-title":"Comparison of gatifloxacin, moxifloxacin and ciprofloxacin for treatment of experimental Burkholderia pseudomallei infection","volume":"55","author":"Steward","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jconrel.2020.11.031_bb0275","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.addr.2014.10.022","article-title":"Inhaled formulations and pulmonary drug delivery systems for respiratory infections","volume":"85","author":"Zhou","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.jconrel.2020.11.031_bb0280","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1021\/acs.molpharmaceut.7b00938","article-title":"Pulmonary delivery of Ceftazidime for the treatment of Melioidosis in a murine model","volume":"15","author":"Ruiz","year":"2018","journal-title":"Mol. Pharm."},{"issue":"11","key":"10.1016\/j.jconrel.2020.11.031_bb0285","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1016\/j.xphs.2016.07.029","article-title":"Formulation and characterization of Nanocluster Ceftazidime for the treatment of acute pulmonary Melioidosis","volume":"105","author":"Ruiz","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2020.11.031_bb0290","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jconrel.2019.02.002","article-title":"Exploitation of the bilosome platform technology to formulate antibiotics and enhance efficacy of melioidosis treatments","volume":"298","author":"D'Elia","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.11.031_bb0295","series-title":"Performance Standards for Antimicrobial Susceptibility Testing","author":"Melvin","year":"2020"},{"key":"10.1016\/j.jconrel.2020.11.031_bib296","doi-asserted-by":"crossref","unstructured":"Yupin Suputtamongkol, Wipada Chaowagul, Ploenchan Chetchotisakd, Nimit Lertpatanasuwun, Sunanta Intaranongpai, Theera Ruchutrakool, Duangkao Budhsarawong, Piroon Mootsikapun, Vanaporn Wuthiekanun, Nitaya Teerawatasook, Aroonlug Lulitanond, Risk Factors for Melioidosis and Bacteremic Melioidosis, Clinical Infectious Diseases, Volume 29, Issue 2, 15 July 1999, Pages 408\u2013413, https:\/\/doi.org\/10.1086\/520223.","DOI":"10.1086\/520223"},{"issue":"7","key":"10.1016\/j.jconrel.2020.11.031_bib297","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1128\/jb.179.7.2116-2125.1997","article-title":"Mutagenesis of Burkholderia pseudomallei with Tn5-OT182: isolation of motility mutants and molecular characterization of the flagellin structural","volume":"179","author":"DeShazer","year":"1997","journal-title":"Journal of Bacteriology Apr"},{"key":"10.1016\/j.jconrel.2020.11.031_bib298","doi-asserted-by":"crossref","unstructured":"Maytal Bivas-Benita, Rapha\u00ebl Zwier, Hans E. Junginger, Gerrit Borchard, Non-invasive pulmonary aerosol delivery in mice by the endotracheal route, European Journal of Pharmaceutics and Biopharmaceutics, Volume 61, Issue 3, 2005, Pages 214-218, ISSN 0939-6411, https:\/\/doi.org\/10.1016\/j.ejpb.2005.04.009.","DOI":"10.1016\/j.ejpb.2005.04.009"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365920306817?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365920306817?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:55:09Z","timestamp":1759161309000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365920306817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":61,"alternative-id":["S0168365920306817"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2020.11.031","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A macrophage-targeted platform for extending drug dosing with polymer prodrugs for pulmonary infection prophylaxis","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2020.11.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}